Celldex Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-73.5M | $-78.7M | $-67.0M | $-56.6M | $-53.8M | $-42.1M | $-35.8M | $-32.8M |
| Depreciation & Amortization | — | $854.0K | — | — | $867.0K | — | — | $775.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $8.5M | — | — | $9.3M | — | — | $7.2M |
| Net Cash from Operating Activities | $-57.4M | $-65.6M | $-48.6M | $-44.0M | $-54.4M | $-55.3M | $-29.3M | $-40.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $3.2M | $1.6M | $440.0K | $728.0K | $265.0K | $545.0K | $274.0K | $344.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $72.1M | — | — | $43.0M | — | — | $-315.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $327.0K | — | — | $202.0K | — | — | $436.1M |
| Net Change in Cash | — | $6.9M | — | — | $-11.2M | — | — | $80.3M |
| Free Cash Flow | $-60.6M | $-67.2M | $-49.1M | $-44.7M | $-54.6M | $-55.9M | $-29.6M | $-41.0M |